Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07395687 · ClinicalTrials.gov registry record · Phase 2
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
A Phase 2 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 333
- Enrollment target
- 3
- Study locations
NCT07395687 is a Phase 2 study of Obesity and Overweight that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 333 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (59% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07395687, a Phase 2 study of Obesity and Overweight, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 333 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG UBT251
Study Locations (3)
California
- Altasciences Clinical LA, Inc. - Cypress
Kansas
- Altasciences Clinical Kansas, Inc. - Overland Park
Quebec
- Altasciences Clinical Company, Inc - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2026-02-02 |
| Est. Completion | 2027-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07395687
The ClinicalTrials.gov registry entry for NCT07395687 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 333 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (59% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07395687 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Kansas, Quebec.
Frequently Asked Questions
What is clinical trial NCT07395687 about?
NCT07395687 is a clinical study titled "A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity". The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants g...
What is the current status of trial NCT07395687?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 333 participants. The study started on 2026-02-02. Estimated completion is 2027-02-18.
What conditions does trial NCT07395687 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07395687?
The interventions under investigation include: Placebo (DRUG), UBT251 (DRUG).
Who is sponsoring clinical trial NCT07395687?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07395687 being conducted?
This trial has 3 study locations across California, Kansas, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.